30 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
such reimbursement.
13. Research Analyst Independence. The Company acknowledges that the Underwriters’ research analysts and research departments are required
8-K
EX-1.1
0xk5s hdpd
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
8-K
EX-1.1
lcxu5 4nr9fnyfl
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm
8-K
EX-99.1
gjm x86rf0r2fknvrr7
10 Jan 20
Regulation FD Disclosure
5:16pm
424B3
vjgio8lwf6l
12 Apr 19
Prospectus supplement
4:41pm